Erlotinib

Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy

SAN FRANCISCO (August 1, 2009)Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer. Both cetuxima...

Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations

...ical lung cancer models." Oncogene. 2008;27:4702-4711. (2) BIBW 2992 and BSC Versus Placebo and BSC in Non-Small Cell Lung Cancer Patients Failing erlotinib or Gefitinib (LUX-LUNG 1). 23 April 2009. Available at: http://clinicaltrials.gov/ct2/show/NCT00656136?term=BIBW+2992+and+Phase+III&rank=1. Acce...

Advanced targeted therapies effective as first-line treatment for lung cancer

...oom 2001-2005, Level 2. EFFICACY AND SAFETY OF erlotinib AS FIRST-LINE MAINTENANCE IN NSCLC FOLLOWING NON-P...M THE PHASE III SATURN STUDY (ABSTRACT # A2.1) erlotinib is an effective and well-tolerated treatment for p...s initiated to evaluate the efficacy and safety of erlotinib as a first-line maintenance therapy following chem...

AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer

...E fficacy S tudy versus T arceva) is a Phase III randomised, double-blind, multi-centre study to assess the efficacy of vandetanib 300mg versus erlotinib in patients with locally advanced or metastatic NSCLC after failure of at least one prior anti-cancer therapy. It enrolled 1240 patients at 171 centre...

Small Molecule Might Play Big Part in Lung Cancer

...xisting or potential therapy. Two recent targeted therapies for specific lung cancers follow this line of scientific thought -- gefitinib (Iressa) and erlotinib (Tarceva). To test their hypothesis that miR-21 and EGFR may make attractive targets for therapy, the researchers tested two experimental compoun...

Damon Runyon Cancer Research Foundation awards $2.7M to 7 top young clinical investigators

...otinib/Tarceva, an EGFR (epidermal growth factor receptor) inhibitor drug, in bladder cancer. His goal is to define predictors of patient response to erlotinib and other EGFR inhibitors and determine how to best coordinate EGFR inhibition with chemotherapy. These studies should have direct clinical impact on...

Drug Combo Proves Powerful Against Lung Cancer

...volving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (... "This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free s...ical Oncology, in Orlando, Fla. Bevacizumab and erlotinib have previously shown promise in treating non-smal...

Study shows drug combination improves outcome for advanced non-small cell lung cancer

... goal of the study was to determine whether adding erlotinib (Tarceva), a targeted agent, to maintenance therap... "This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free s...tients were randomized to receive bevacizumab plus erlotinib or bevacizumab plus placebo after initial cytotoxi...

'Happy hour' gene discovery suggests cancer drugs might treat alcoholism

...gs designed to inhibit the EGF receptor, including erlotinib (trade name Tarceva) and gefitinib (trade name Ire... researchers show that flies and mice treated with erlotinib also grow more sensitive to alcohol. What's more, ...iversity of California, San Francisco, noting that erlotinib and gefitinib, along with other EGFR inhibitors, n...

May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO

...ts with SCCHN who were treated with gefitinib (G), erlotinib and bevacizumab (E/B), cetuximab (C), or palliative chemotherapy (PC). Gefitinib, erlotinib and cetuximab are EGFRIs with activity in SCCHN. ...enetic features with survival after treatment with erlotinib in patients with NSCLC will also be presented on S...

Erlotinib in Medical Technology

SuperGen's MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib

Data support MP-470's role in overcoming erlotinib resistance DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological mal...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

..., vandetanib was shown to have similar efficacy to erlotinib for PFS and OS (PFS: hazard ratio [HR] 0.98, 95.22...evaluating the efficacy of vandetanib 300mg versus erlotinib 150mg. The study enrolled 1240 patients with local...009. (3) Natale, R. et al. Vandetanib versus erlotinib in patients with advanced non-small-cell lung canc...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

...nitially respond to EGFR TKIs such as gefitinib or erlotinib will eventually develop resistance, often through ...ine or third-line reversible EGFR inhibitor (i.e., erlotinib or gefitinib). This study recently moved from Phas...BSC in Non-Small Cell Lung Cancer Patients Failing erlotinib or Gefitinib (LUX-LUNG 1)" 23 April 2009. Clinical...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting

...le of presentations is as follows: Date Time (PDT) Abstract # and Title Sunday, 8 a.m. - 12 p.m. #671 -- Inhibition of erlotinib resistance April 13 on HER-family tyrosine kinases by combination with MP-470, a ...

Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer

...se 1 part of the study, safety and pharmacokinetics of combining XL184 with erlotinib will be evaluated. The primary endpoint of the phase 2 part of the study is...al of XL184, in combination with erlotinib. Subsequent cohorts will receive erlotinib in combination with escalating doses of XL184 until the MTD is reached. In ...

AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer

...ata from the study is expected in 2008. ZEST is a randomized, double-blind, multi-center Phase III study to assess the efficacy of vandetanib versus erlotinib in overall survival (OS) and progression-free survival (PFS) in over 1,150 patients with locally-advanced or metastatic non-small cell lung cancer (NS...

Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting

...a Commonwealth University and Massey Cancer Center are authors. Abstract #2484 "Histone deacetylase inhibitor FK228 enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines" will be presented in an oral session on Monday April 16 from 11:55 am - 12:10 pm. Dr. Wei Zhang et a...

Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting

... protein inhibitor in combination Ascenta with the ErbB1 tyrosine kinase Therapeutics inhibitor erlotinib (Tarceva(R)) ---------------------------------- -------------- A novel pan inhibitor of Bcl-2 and Xiongwen ...

AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer

...t AV-412 is greater than 10 times more potent than erlotinib in genetically engineered lung tumor models with t... Annual Meeting. The molecularly targeted drugs - erlotinib (Tarceva(R)) and gefitinib (Iressa(R)) - inhibit E...tion of resistance mutations within the EGFR gene. erlotinib and gefitinib have no effect on the EGFR L858R/T79...

Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting

... study examining the combination of romidepsin and erlotinib in non-small cell lung cancer (NSCLC) cell lines d...inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines" ...mbination with the tyrosine kinase inhibitor (TKI) erlotinib in NSCLC. In the in vitro arm of the study, 22 NSC...

Erlotinib in Medical Dictionary

Adrenocortical carcinoma

...revention, and prognosis. Adjuvant Mitotane Treatment for Adrenocortical Carcinoma ... Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. ... Home > Research > Clinical Translational Research > Adrenocortical Carcinoma Research Program ... Treatments fo...

Erlotinib in Biological News

Newly discovered epidermal growth factor receptor active in human pancreatic cancers

...alized the same receptor had been found by other researchers to be activated in a subset of lung cancers. And, most promising, an EGFR inhibitor named erlotinib already has been through the long and complex Food and Drug Administration approval process and is in use for treatment of these specific lung cancers...

Biomarkers allow doctors to match therapy to patient

...d with bevacizumab and erlotinib, ccEPC levels increased, while free plasma VEGF levels decreased. ccEPCs did not rise in a control group treated with erlotinib alone, Vroling said. These data suggest that ccEPCs are increased in cancer patients in an anti-angiogenic, treatment-specific way, she said. Furt...

Treatments have same target, different responses for lung cancer patients with genetic mutation

...vates signaling pathways involved with cell growth and survival. Previous studies have shown that small-molecule EGFR inhibitors such as gefitinib and erlotinib (Tarceva) work by blocking signals in the intracellular domain of EGFR--between the EGFR and the cell nucleus. Additionally, many NSCLC patients with ...

Erlotinib in Biological Technology

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

...9:45 a.m. - 11:15 a.m., Level 2, West Hall F3 Lung Cancer A Phase 2 Study of Sorafenib and erlotinib in Chemotherapy-Naive Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer Joline S. Lind, M.D., Department of Pulmonary...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

...or effects of nab-rapamycin (ABI-009) in combination with kinase inhibitors erlotinib and Perifosine Author(s): Neil Desai, Osmond D'Cruz, Vuong Trieu. Abra... that rapamycin is active only on mTORC1 and inhibition of mTORC2 by either erlotinib or Perifosine is necessary to achieve complete shutdown of mTOR signaling p...

Mylan Confirms Four First-to-File Challenges

... the U.S. District Court in Delaware in connection with the ANDA filing for erlotinib Hydrochloride (HCl) Tablets, 25 mg, 100 mg and 150 mg. erlotinib HCl Tablets are the generic version of OSI Pharmaceuticals' lung cancer tre...

SuperGen Reports 2008 Second Quarter Financial Results

...nsitize prostate and breast cancer cells to erlotinib (Abstract No. 671). The presentation entitled, "Inhibition of erlotinib resistance on HER-family tyrosine kinases b...ggesting that the combination of MP-470 and erlotinib inhibits the binding of the p85 subunit of ...

Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial

...g into broader commercial markets by demonstrating activity in major tumor types. A phase 1/2 trial of XL184 as a single agent and in combination with erlotinib was recently initiated in patients with non- small cell lung cancer. In addition, a phase 2 study of XL184 in patients with glioblastoma multiforme is...

SuperGen Reports 2008 First Quarter Financial Results

...nsitize prostate and breast cancer cells to erlotinib (Abstract No. 671). The presentation entitled, "Inhibition of erlotinib resistance on HER-family tyrosine kinases b...dicating that the combination of MP-470 and erlotinib inhibits the binding of the p85 subunit of ...

Eric K. Rowinsky Joins ADVENTRX Board of Directors

...d integrally involved in pivotal clinical and preclinical investigations which led to the development of paclitaxel, docetaxel, topotecan, irinotecan, erlotinib and gefitinib, among others. Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and/or Editorial Board Member of ...